Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with ...

Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...
Le Lézard

PADCEVtm Plus KEYTRUDAtm, Given Before and After Surgery, Cuts the Risk of Recurrence ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...
EL PAÍS English

Drones are changing the face of war and attracting multi-million dollar investments

It’s the biggest battlefield innovation in a generation.” Last July, U.S. Secretary of Defense Pete Hegseth acknowledged an ...

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a ...

(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...